ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor alterationsFirst-line osimertinibSafety of osimertinibProgression-free survivalDuration of responseNovel drug combinationsData cutoffPartial responseOsimertinib resistanceRisk-benefit analysisOverall survivalReceptor alterationsDiscontinued treatmentInvestigator assessmentClinical benefitNecitumumabSafety profileOsimertinibReport final resultsAdverse eventsDrug combinations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply